Cargando…
Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene
OBJECTIVE: To explore the mechanism of miR-195-5p in the pathogenesis non-small cell lung cancer (NSCLC) and cisplatin resistance. METHODS: The function of miR-195-5p in NSCLC and cisplatin resistance were determined by MTT, scratch assay, transwell assay, and nude mice xenograft experiments. miR-19...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092352/ https://www.ncbi.nlm.nih.gov/pubmed/33953601 http://dx.doi.org/10.2147/PGPM.S302755 |
_version_ | 1783687645385195520 |
---|---|
author | Wang, Hao Sui, Zhi-lin Wu, Xian-xian Tang, Peng Zhang, Hong-dian Yu, Zhen-tao |
author_facet | Wang, Hao Sui, Zhi-lin Wu, Xian-xian Tang, Peng Zhang, Hong-dian Yu, Zhen-tao |
author_sort | Wang, Hao |
collection | PubMed |
description | OBJECTIVE: To explore the mechanism of miR-195-5p in the pathogenesis non-small cell lung cancer (NSCLC) and cisplatin resistance. METHODS: The function of miR-195-5p in NSCLC and cisplatin resistance were determined by MTT, scratch assay, transwell assay, and nude mice xenograft experiments. miR-195-5p target gene was identified by dual-luciferase reporter assays and real-time PCR analysis. RESULTS: miR-195-5p content was lower in A549/DDP than that in A549 cells, with reduced chemotherapy sensitivity and increased cell invasion and migration ability. The loss-of-function and gain-of-function assays illustrated that miR-195-5p might have increased the chemosensitivity to cisplatin in the A549/DDP cells and decreased cell migration and invasion. FGF2 is a negatively correlated action target of miR-195-5p. miR-195-5p might affect EMT by inhibiting FGF2. Overexpression of FGF2 resulted in enhanced cisplatin resistance in the cells, while miR-195-5p might have reversed this resistance. CONCLUSION: Overall, miR-195-5p might target FGF2 to reduce cisplatin resistance in A549/DDP cells and enhance chemosensitivity. |
format | Online Article Text |
id | pubmed-8092352 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-80923522021-05-04 Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene Wang, Hao Sui, Zhi-lin Wu, Xian-xian Tang, Peng Zhang, Hong-dian Yu, Zhen-tao Pharmgenomics Pers Med Original Research OBJECTIVE: To explore the mechanism of miR-195-5p in the pathogenesis non-small cell lung cancer (NSCLC) and cisplatin resistance. METHODS: The function of miR-195-5p in NSCLC and cisplatin resistance were determined by MTT, scratch assay, transwell assay, and nude mice xenograft experiments. miR-195-5p target gene was identified by dual-luciferase reporter assays and real-time PCR analysis. RESULTS: miR-195-5p content was lower in A549/DDP than that in A549 cells, with reduced chemotherapy sensitivity and increased cell invasion and migration ability. The loss-of-function and gain-of-function assays illustrated that miR-195-5p might have increased the chemosensitivity to cisplatin in the A549/DDP cells and decreased cell migration and invasion. FGF2 is a negatively correlated action target of miR-195-5p. miR-195-5p might affect EMT by inhibiting FGF2. Overexpression of FGF2 resulted in enhanced cisplatin resistance in the cells, while miR-195-5p might have reversed this resistance. CONCLUSION: Overall, miR-195-5p might target FGF2 to reduce cisplatin resistance in A549/DDP cells and enhance chemosensitivity. Dove 2021-04-28 /pmc/articles/PMC8092352/ /pubmed/33953601 http://dx.doi.org/10.2147/PGPM.S302755 Text en © 2021 Wang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Wang, Hao Sui, Zhi-lin Wu, Xian-xian Tang, Peng Zhang, Hong-dian Yu, Zhen-tao Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene |
title | Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene |
title_full | Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene |
title_fullStr | Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene |
title_full_unstemmed | Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene |
title_short | Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene |
title_sort | reversal of chemotherapy resistance to cisplatin in nsclc by mirna-195-5p via targeting the fgf2 gene |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092352/ https://www.ncbi.nlm.nih.gov/pubmed/33953601 http://dx.doi.org/10.2147/PGPM.S302755 |
work_keys_str_mv | AT wanghao reversalofchemotherapyresistancetocisplatininnsclcbymirna1955pviatargetingthefgf2gene AT suizhilin reversalofchemotherapyresistancetocisplatininnsclcbymirna1955pviatargetingthefgf2gene AT wuxianxian reversalofchemotherapyresistancetocisplatininnsclcbymirna1955pviatargetingthefgf2gene AT tangpeng reversalofchemotherapyresistancetocisplatininnsclcbymirna1955pviatargetingthefgf2gene AT zhanghongdian reversalofchemotherapyresistancetocisplatininnsclcbymirna1955pviatargetingthefgf2gene AT yuzhentao reversalofchemotherapyresistancetocisplatininnsclcbymirna1955pviatargetingthefgf2gene |